

Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer

Information for the public

Published: 12 July 2023

www.nice.org.uk

Lorlatinib (Lorviqua) is not normally available on the NHS for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have not had an ALK inhibitor.

Your doctor should talk with you about other treatment options. If you are already having it, you should be able to continue until you and your doctor decide when best to stop.

Information and support

The [NHS webpage on lung cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [ALK Positive UK, hello@alkpositive.org.uk](mailto:hello@alkpositive.org.uk)
- [Roy Castle Lung Cancer Foundation](#), 0333 323 7200
- [Lung Cancer Nursing UK \(LCNUK\)](#), 01675 477607
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5283-0